Literature DB >> 21543487

Kaposi's sarcoma-associated herpesvirus infection of endothelial cells inhibits neutrophil recruitment through an interleukin-6-dependent mechanism: a new paradigm for viral immune evasion.

L M Butler1, H C Jeffery, R L Wheat, P C Rae, K Townsend, K R Alkharsah, T F Schulz, G B Nash, D J Blackbourn.   

Abstract

Kaposi's sarcoma-associated herpesvirus (KSHV) is the etiological agent of Kaposi's sarcoma (KS), an endothelial cell (EC) neoplasm characterized by dysregulated angiogenesis and inflammation. KSHV infection of EC causes production of proinflammatory mediators, regarded as possible initiators of the substantial mononuclear leukocyte recruitment seen in KS. Conversely, KSHV immune evasion strategies exist, such as degradation of EC leukocyte adhesion receptors by viral proteins. Here, we report the effects of KSHV infection of primary EC on recruitment of flowing leukocytes. Infection did not initiate adhesion of any leukocyte subset per se. However, on cytokine-stimulated EC, KSHV specifically inhibited neutrophil, but not PBL or monocyte, transmigration, an observation consistent with the inflammatory cell profile found in KS lesions in vivo. This inhibition could be recapitulated on uninfected EC using supernatant from infected cultures. These supernatants contained elevated levels of human interleukin 6 (hIL-6), and both the KSHV- and the supernatant-induced inhibitions of neutrophil transmigration were abrogated in the presence of a hIL-6 neutralizing antibody. Furthermore, preconditioning of EC with hIL-6 mimicked the effect of KSHV. Using RNA interference (RNAi), we show that upregulation of suppressor of cytokine signaling 3 (SOCS3) was necessary for this effect of hIL-6. These studies reveal a novel paracrine mode of KSHV immune evasion, resulting in reduced recruitment of neutrophils, a cell type whose antiviral and antitumor roles are becoming increasingly appreciated. Moreover, the findings have implications for our understanding of the contribution of hIL-6 to the pathogenesis of other inflammatory disorders and tumors in which this cytokine is abundant.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21543487      PMCID: PMC3126554          DOI: 10.1128/JVI.00021-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  81 in total

1.  Induction of chemokine production by latent Kaposi's sarcoma-associated herpesvirus infection of endothelial cells.

Authors:  Yiyiang Xu; Don Ganem
Journal:  J Gen Virol       Date:  2007-01       Impact factor: 3.891

Review 2.  Significance of interleukin-6 (IL-6) in breast cancer (review).

Authors:  Heike Knüpfer; Rainer Preiss
Journal:  Breast Cancer Res Treat       Date:  2006-08-23       Impact factor: 4.872

3.  Mechanisms of growth control of Kaposi's sarcoma-associated herpes virus-associated primary effusion lymphoma cells.

Authors:  H Asou; J W Said; R Yang; R Munker; D J Park; N Kamada; H P Koeffler
Journal:  Blood       Date:  1998-04-01       Impact factor: 22.113

4.  Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells.

Authors:  K A Staskus; W Zhong; K Gebhard; B Herndier; H Wang; R Renne; J Beneke; J Pudney; D J Anderson; D Ganem; A T Haase
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

5.  Suppressor of cytokine signaling 3 (SOCS3) limits damage-induced crypt hyper-proliferation and inflammation-associated tumorigenesis in the colon.

Authors:  R J Rigby; J G Simmons; C J Greenhalgh; W S Alexander; P K Lund
Journal:  Oncogene       Date:  2007-02-12       Impact factor: 9.867

Review 6.  The inflammatory component of Kaposi sarcoma.

Authors:  Liron Pantanowitz; Ashlee V Moses; Bruce J Dezube
Journal:  Exp Mol Pathol       Date:  2009-07-08       Impact factor: 3.362

Review 7.  The contribution of systems biology and reverse genetics to the understanding of Kaposi's sarcoma-associated herpesvirus pathogenesis in endothelial cells.

Authors:  Michael Stürzl; Andreas Konrad; Khaled R Alkharsah; Ramona Jochmann; Mathias Thurau; Gaby Marquardt; Thomas F Schulz
Journal:  Thromb Haemost       Date:  2009-12       Impact factor: 5.249

8.  Synergistic cytolysis mediated by hydrogen peroxide combined with peptide defensins.

Authors:  A K Lichtenstein; T Ganz; M E Selsted; R I Lehrer
Journal:  Cell Immunol       Date:  1988-06       Impact factor: 4.868

9.  Defensins. Natural peptide antibiotics of human neutrophils.

Authors:  T Ganz; M E Selsted; D Szklarek; S S Harwig; K Daher; D F Bainton; R I Lehrer
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

10.  Highly selective escape from KSHV-mediated host mRNA shutoff and its implications for viral pathogenesis.

Authors:  Britt Glaunsinger; Don Ganem
Journal:  J Exp Med       Date:  2004-08-02       Impact factor: 14.307

View more
  16 in total

1.  Kaposi's sarcoma-associated herpesvirus inhibits expression and function of endothelial cell major histocompatibility complex class II via suppressor of cytokine signaling 3.

Authors:  L M Butler; H C Jeffery; R L Wheat; H M Long; P C Rae; G B Nash; D J Blackbourn
Journal:  J Virol       Date:  2012-04-24       Impact factor: 5.103

Review 2.  The effect of environmental chemicals on the tumor microenvironment.

Authors:  Stephanie C Casey; Monica Vaccari; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Mary Helen Barcellos-Hoff; Dustin G Brown; Marion Chapellier; Joseph Christopher; Colleen S Curran; Stefano Forte; Roslida A Hamid; Petr Heneberg; Daniel C Koch; P K Krishnakumar; Ezio Laconi; Veronique Maguer-Satta; Fabio Marongiu; Lorenzo Memeo; Chiara Mondello; Jayadev Raju; Jesse Roman; Rabindra Roy; Elizabeth P Ryan; Sandra Ryeom; Hosni K Salem; A Ivana Scovassi; Neetu Singh; Laura Soucek; Louis Vermeulen; Jonathan R Whitfield; Jordan Woodrick; Annamaria Colacci; William H Bisson; Dean W Felsher
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

3.  Suppressor of Cytokine Signaling 1 (SOCS1) and SOCS3 Are Stimulated within the Eye during Experimental Murine Cytomegalovirus Retinitis in Mice with Retrovirus-Induced Immunosuppression.

Authors:  Hsin Chien; Christine I Alston; Richard D Dix
Journal:  J Virol       Date:  2018-08-29       Impact factor: 5.103

Review 4.  Infection and immune control of human oncogenic γ-herpesviruses in humanized mice.

Authors:  Donal McHugh; Nicole Caduff; Anita Murer; Christine Engelmann; Yun Deng; Hana Zdimerova; Kyra Zens; Obinna Chijioke; Christian Münz
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2019-05-27       Impact factor: 6.237

5.  Human cytomegalovirus induces a biphasic inflammatory response in primary endothelial cells.

Authors:  H C Jeffery; C Söderberg-Naucler; L M Butler
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103

Review 6.  Interplay between Kaposi's sarcoma-associated herpesvirus and the innate immune system.

Authors:  Kevin Brulois; Jae U Jung
Journal:  Cytokine Growth Factor Rev       Date:  2014-06-21       Impact factor: 7.638

Review 7.  Immune control of oncogenic γ-herpesviruses.

Authors:  Jae Jung; Christian Münz
Journal:  Curr Opin Virol       Date:  2015-09-13       Impact factor: 7.090

8.  Bone Morphogenetic Protein 9 Enhances Lipopolysaccharide-Induced Leukocyte Recruitment to the Vascular Endothelium.

Authors:  Edwin R Chilvers; Nicholas W Morrell; Sarah L Appleby; Claudia-Gabriela Mitrofan; Alexi Crosby; Kim Hoenderdos; Katharine Lodge; Paul D Upton; Clara M Yates; Gerard B Nash
Journal:  J Immunol       Date:  2016-09-19       Impact factor: 5.422

9.  Podocytes regulate neutrophil recruitment by glomerular endothelial cells via IL-6-mediated crosstalk.

Authors:  Sahithi J Kuravi; Helen M McGettrick; Simon C Satchell; Moin A Saleem; Lorraine Harper; Julie M Williams; George Ed Rainger; Caroline O S Savage
Journal:  J Immunol       Date:  2014-05-28       Impact factor: 5.422

10.  Infection and transmission dynamics of rKSHV.219 in primary endothelial cells.

Authors:  Hannah C Jeffery; Rachel L Wheat; David J Blackbourn; Gerard B Nash; Lynn M Butler
Journal:  J Virol Methods       Date:  2013-06-10       Impact factor: 2.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.